BofA analyst Michael Ryskin raised the firm’s price target on Iqvia (IQV) to $260 from $245 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target raised to $230 from $200 at Barclays
- IQVIA Holdings Amends Credit Agreement for Refinancing
- Jefferies says market thinking ‘backwards’ on FDA one trial proposal
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports